Allarity Therapeutics, Inc. — Form 8-K
Filed November 17, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 72/100
What the filing says
On November 12, 2026, Allarity Therapeutics exchanged $3,000,000 of its $10,930,000 Promissory Note (dated March 2, 2026) owed to Streeterville Capital, LLC for 3,000 shares of newly designated Series B Preferred Stock with a stated value of $1,050 per share ($3.15M total). The Series B carries a 9% annual preferred return (15% if default occurs), senior liquidation rights, and grants Streeterville broad protective covenants including restrictions on future issuances, asset pledges, and fundamental transactions. Separately, Streeterville consented to Allarity's use of an at-the-market (ATM) facility for common stock sales, requiring Allarity to pay Streeterville 33% of ATM net proceeds weekly (applied to Series B redemption or Note repayment as Streeterville elects). The Note balance was reduced to $7,930,000 post-exchange.
Why this rating
Material debt-to-equity restructuring with a creditor now owning senior preferred equity (~$3.15M) and holding restrictive covenants over a ~$14.7M market-cap company. 33% ATM sweep is onerous dilution tax. Significant for capital structure.
Tradability signal
NO TRADE
No trade: only ~$53k traded in the last 30 min — too illiquid to enter and exit. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it negative)
at our read · unknown $0.88 | +10 min · unknown $0.88 ▼ 0.34% | +30 min · unknown $0.88 ▼ 0.28% | +1 hr · unknown $0.84 ▼ 3.81% | +4 hrs · unknown $0.84 ▼ 4.00% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.